Abstract：Muscle-invasive bladder cancer (MIBC) refers to the bladder cancer with clinical stage of cT2-cT4a. MIBC is characterized by the fast progress, apt to recurrence, likely to distant metastasis, high malignancy and high mortality. At present, radical cystectomy (RC) plus pelvic lymph node dissection (PLND) is considered the standard treatment for MIBC. However, the 5-year survival rate of patients with MIBC remains low, ranging from 27%-67%. In order to improve the oncological outcome, guidelines recommend cisplatin-based neoadjuvant chemotherapy for the treatment of patients with MIBC. Neoadjuvant chemotherapy could improve the 5-year survival of MIBC. This article reviews the optimal chemotherapy regimens, current status and future issues of the neoadjuvant chemotherapy.
[1]Siegel R, Ma J, Zou Z, et al. Cancer statistics 2014. CA Cancer J Clin, 2014,64(1):9-29. [2]Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come. CA Cancer J Clin, 2010,60(4):244-272. [3]Feifer AH, Taylor JM, Tarin TV, et al. Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. Eur Urology, 2011,59(6):978-984. [4]Fairey AS, Daneshmand S, Quinn D, et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblast/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of South-California. Urol Oncol, 2013,31(8):1737-1743. [5]Leow JJ, Fay AP, Mullane SA, et al. Perioperative therapy for muscle invasive bladder cancer. Hematol Oncol Clin North Am, 2015, 29(2):301-318. [6]曹明,赵宏,穆鑫,等.吉西他滨联合顺铂方案新辅助化疗联合全膀胱切除术治疗肌层浸润性膀胱癌的9年回顾性分析. 中华泌尿外科杂志, 2014, 35(1):49-53. [7]魏晓龙, 郭和清. 晚期膀胱癌化疗进展. 微创泌尿外科杂志, 2013, 2(2):146-150. [8]Takata R, Katagiri T, Kanehira M, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res, 2005,11(7):2625-2636. [9]Stein JP. Contemporary concepts of radical cystectomy and the treatment of bladder cancer. J Urol, 2003,169(1):116-117. [10]Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol, 2004,171(2 Pt 1):561-569. [11]Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet, 2003,361(9373):1927-1934. [12]Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient date advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol, 2005,48(2):202-205. [13]Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 2003,349(9):859-866. [14]von der Maase H, Sengelov L, Roberts J T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol, 2005,23(21):4602-4608. [15]Morales-Barrera R, Bellmunt J, Su^ez C, et al. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer, 2012,48(12):1816-1821. [16]Bamias A, Dafni U, Karadimou A, et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol, 2013,24(4):1011-1017. [17]Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol, 2012,23(2):406-410. [18]de Vere White RW, Lara Jr PN, Goldman B, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol, 2009,181(6):2476-2481. [19]Iyer G, Al-Ahmadie H, Schultz N, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol, 2013,31(25):3133-3140. [20]Sternberg CN, Pansadoro V, Calabro F, et al. Can patient seleclion for bladder preservation be based on response to chemotherapy. Cancer, 2003, 97(7):1644-1652. [21]Stordal B, Davey R. A systematic review of genes involved in the inverse resistance relationship between dsplatin and paclitaxel chemotherapy: role of BRCAI. Curr Cancer Drug Targets, 2009,9(3):354-365. [22]Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Onco1, 2011,22(1):139-144. [23]Kawashima A, Nakayama M, Kakuta Y, et al. Excision repair cross-complementing group l may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res, 2011,17(8):2561-2569. [24]HofmannAC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia, 2010,12(8):628-636. [25]Feifer AH, Taylor JM, Tarin TV, et al. Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. Eur Urol, 2011,59(6):978-984. [26]Burger M, Mulders P, Witjes W. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. Eur Urol, 2012,61(5):1070-1071.
